DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis

Vestergaard, 2009, Bone metabolism in type 2 diabetes and role of thiazolidinediones, Curr Opin Endocrinol Diabetes Obes, 16, 125, 10.1097/MED.0b013e328325d155 Tuominen, 1999, Bone mineral density in patients with type 1 and type 2 diabetes, Diabetes Care, 22, 1196, 10.2337/diacare.22.7.1196 Wallace, 2002, Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer, Diabetes Care, 25, 1983, 10.2337/diacare.25.11.1983 Carnevale, 2004, Skeletal involvement in patients with diabetes mellitus, Diabetes Metab Res Rev, 20, 196, 10.1002/dmrr.449 Montagnani, 2013, Antidiabetic therapy effects on bone metabolism and fracture risk, Diabetes Obes Metab, 15, 784, 10.1111/dom.12077 Grey, 2009, Thiazolidinedione-induced skeletal fragility – mechanisms and implications, Diabetes Obes Metab, 11, 275, 10.1111/j.1463-1326.2008.00931.x Yaturu, 2007, Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men, Diabetes Care, 30, 1574, 10.2337/dc06-2606 Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224 Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 Monami, 2008, Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study, Diabetes Care, 31, 199, 10.2337/dc07-1736 Schwartz, 2002, Older women with diabetes have a higher risk of falls: a prospective study, Diabetes Care, 25, 1749, 10.2337/diacare.25.10.1749 Ivers, 2001, Diabetes and risk of fracture: the Blue Mountains eye study, Diabetes Care, 24, 1198, 10.2337/diacare.24.7.1198 Stolk, 1996, Hyperinsulinemia and bone mineral density in an elderly population: the Rotterdam study, Bone, 18, 545, 10.1016/8756-3282(96)00079-8 Baetta, 2011, Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences, Drugs, 71, 1441, 10.2165/11591400-000000000-00000 Vestergaard, 2007, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a meta-analysis, Osteoporos Int, 18, 427, 10.1007/s00198-006-0253-4 Lipscombe, 2007, The risk of hip fractures in older individuals with diabetes: a population-based study, Diabetes Care, 30, 835, 10.2337/dc06-1851 Monami, 2011, Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials, Diabetes Care, 34, 2474, 10.2337/dc11-1099 Higgins, 2008, Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified, Int J Epidemiol, 37, 1158, 10.1093/ije/dyn204 Egger, 1997, Meta-analysis: potentials and promise, BMJ, 315, 1371, 10.1136/bmj.315.7119.1371 Halpern, 2007, Appendix: Jadad scale for reporting randomized controlled trials, 237 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Sterne, 2001, Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis, J Clin Epidemiol, 54, 1046, 10.1016/S0895-4356(01)00377-8 Rosenstock, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 28, 1556, 10.1016/j.clinthera.2006.10.007 Henry, 2014, Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study, Diabetes Obes Metab, 16, 223, 10.1111/dom.12194 NCT00856284, 2013 Arechavaleta, 2011, Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial, Diabetes Obes Metab, 13, 160, 10.1111/j.1463-1326.2010.01334.x Charbonnel, 2013, Diabetologia, 56, 1503, 10.1007/s00125-013-2905-1 Goke, 2013, Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial, Int J Clin Pract, 67, 307, 10.1111/ijcp.12119 Schernthaner, 2013, Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial, Diabetes Care, 36, 2508, 10.2337/dc12-2491 Wainstein, 2012, Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes, Diabetes Obes Metab, 14, 409, 10.1111/j.1463-1326.2011.01530.x Iwamoto, 2010, Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial, Diabetes Obes Metab, 12, 613, 10.1111/j.1463-1326.2010.01197.x Alba, 2013, Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function, Diabetes Obes Metab, 15, 1101, 10.1111/dom.12145 NCT00374907. A study assessing saxagliptin treatment in subjects with type 2 diabetes who are not controlled with diet and exercise; 2015 Available from: <https://clinicaltrials.gov/ct2/show/NCT00374907> [7.10.15]. NCT00968708. Cardiovascular outcomes study of alogliptin in patients with type 2 diabetes and acute coronary syndrome (EXAMINE); 2014. NCT01006603, Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION); 2013. NCT00984867. Dapagliflozin DPPIV inhibitor add-on study; 2014. NCT00286468. Study of alogliptin combined with sulfonylurea in subjects with type 2 diabetes mellitus; 2012. DeFronzo, 2012, Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes, J Clin Endocrinol Metab, 97, 1615, 10.1210/jc.2011-2243 NCT00734474. A study of LY2189265 compared to sitagliptin in participants with type 2 diabetes mellitus on metformin; 2015. Scherbaum, 2008, Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia, Diabetes Obes Metab, 10, 675, 10.1111/j.1463-1326.2008.00850.x NCT00800683. Safety and efficacy in type 2 diabetic patients with severe chronic renal impairment; 2014. NCT01098539. A study of the efficacy and safety of albiglutide in subjects with type 2 diabetes with renal impairment; 2014. Arjona Ferreira, 2013, Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial, Am J Kidney Dis, 61, 579, 10.1053/j.ajkd.2012.11.043 Arjona Ferreira, 2013, Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency, Diabetes Care, 36, 1067, 10.2337/dc12-1365 NCT00707993. Efficacy and safety of alogliptin compared to glipizide in elderly diabetics; 2013. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Baggio, 2007, Biology of incretins: GLP-1 and GIP, Gastroenterology, 132, 2131, 10.1053/j.gastro.2007.03.054 Seino, 2010, GIP and GLP-1, the two incretin hormones: similarities and differences, J Diabetes Invest, 1, 8, 10.1111/j.2040-1124.2010.00022.x Glorie, 2014, DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats, Am J Physiol Endocrinol Metab, 307, E447, 10.1152/ajpendo.00217.2014 Kyle, 2011, Differential effects of PPAR-γ activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice, Endocrinology, 152, 457, 10.1210/en.2010-1098 Garber, 2008, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea∗, Diabetes Obes Metab, 10, 1047, 10.1111/j.1463-1326.2008.00859.x NCT00396357. Safety of vildagliptin and metformin combination therapy in patients with type 2 diabetes not well controlled with metformin alone; 2012. NCT00698932. Evaluate efficacy and safety of saxagliptin in adult patients with type 2 diabetes inadequate glycemic control; 2011. Su, 2014, Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials, Endocrine, 48, 107, 10.1007/s12020-014-0361-4 Scirica, 2013, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, 369, 1317, 10.1056/NEJMoa1307684 Driessen, 2014, Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture, Bone, 68, 124, 10.1016/j.bone.2014.07.030 Aschner, 2010, Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes, Diabetes Obes Metab, 12, 252, 10.1111/j.1463-1326.2009.01187.x Barnett, 2013, Linagliptin for patients aged 70years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial, Lancet, 382, 1413, 10.1016/S0140-6736(13)61500-7 Chacra, 2009, Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, Int J Clin Pract, 63, 1395, 10.1111/j.1742-1241.2009.02143.x Dobs, 2013, Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes, J Diabetes, 5, 68, 10.1111/j.1753-0407.2012.00223.x Fonseca, 2007, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes, Diabetologia, 50, 1148, 10.1007/s00125-007-0633-0 Fonseca, 2013, Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes, J Diabetes Complications, 27, 177, 10.1016/j.jdiacomp.2012.09.007 Goldstein, 2007, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes, Diabetes Care, 30, 1979, 10.2337/dc07-0627 Hollander, 2011, Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus, Diab Vasc Dis Res, 8, 125, 10.1177/1479164111404575 Jadzinsky, 2009, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial, Diabetes Obes Metab, 11, 611, 10.1111/j.1463-1326.2009.01056.x Nauck, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabetes Obes Metab, 9, 194, 10.1111/j.1463-1326.2006.00704.x Vilsbøll, 2010, Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes, Diabetes Obes Metab, 12, 167, 10.1111/j.1463-1326.2009.01173.x Yang, 2011, Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial, Diabetes Res Clin Pract, 94, 217, 10.1016/j.diabres.2011.07.035 Yoon, 2011, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes, Int J Clin Pract, 65, 154, 10.1111/j.1742-1241.2010.02589.x